Cover Image
市場調查報告書

綠膿桿菌肺炎:開發中產品分析

Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484628
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
綠膿桿菌肺炎:開發中產品分析 Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 32 Pages
簡介

綠色膿菌是造成肺炎重要的原因,是住院一周以上的患者中檢驗出最常見的病原體。體徵和症狀包括發燒,疲勞,瘙癢,出血性潰瘍和頭痛。危險因素包括年齡和免疫系統減弱。治療有使用抗生素等。

本報告提供全球各國治療綠膿桿菌肺炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

綠膿桿菌肺炎;概要

綠膿桿菌肺炎 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aridis Pharmaceuticals LLC
  • Emergent BioSolutions Inc
  • MedImmune LLC
  • Polyphor Ltd

藥物簡介

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9679IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2017, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pseudomonas aeruginosa Pneumonia - Overview
    • Pseudomonas aeruginosa Pneumonia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals LLC
    • Emergent BioSolutions Inc
    • MedImmune LLC
    • Polyphor Ltd
  • Pseudomonas aeruginosa Pneumonia - Drug Profiles
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects
  • Pseudomonas aeruginosa Pneumonia - Product Development Milestones
    • Featured News & Press Releases
      • Aug 02, 2017: Aridis Pharmaceuticals Enrolls First Patients in Global Pivotal Clinical Trial of Novel Monoclonal Antibody for Treating Acute Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2017
  • Pseudomonas aeruginosa Pneumonia - Pipeline by MedImmune LLC, H2 2017
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Polyphor Ltd, H2 2017
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top